Capabilities & Services

Every engagement at Pharmath Consulting starts with your scientific question — not a pre-packaged deliverable. We work across therapeutic areas and development stages, bringing the same mechanistic rigor to a focused feasibility analysis as to a full QSP platform build. Our clients range from early-stage biotechs validating a target to clinical-stage programs preparing regulatory submissions.

Model-Informed Drug Development (MIDD / MID3)

We deploy comprehensive quantitative modeling and simulation frameworks across the entire development pipeline. By integrating preclinical data and clinical knowledge, we create a unified strategy to accelerate asset timelines and optimize trial designs.

Mechanistic PK/PD & Quantitative Systems Pharmacology (QSP)

We build mechanistic modeling frameworks that incorporate deep biological rationale to evaluate target feasibility and candidate properties. From determining the precise binding affinity needed to meet your Target Product Profile (TPP) to evaluating pathway suitability for complex diseases, our models scale seamlessly in complexity to fit your specific programmatic questions.

Early Feasibility & Competitive Benchmarking

When evaluating an initial biological concept or selecting from multiple early-stage candidates, we build focused mechanistic models to map the exact parameter space where your TPP can be achieved. These questions are often best answered in the context of the competitive landscape — by directly benchmarking your molecule's properties against clinical competitors. We help your discovery team answer the foundational questions with clarity: Is this the right target? Does our molecule have what it takes to win?

Mechanistic Model-Based Meta-Analysis (MBMA)

When navigating a competitive therapeutic landscape, you need to know exactly how your asset stacks up. We build sophisticated mechanistic MBMA frameworks, integrating your internal data with extracted competitor data, to evaluate the specific molecular properties required to meet or exceed the clinical outcomes of competing programs.

Disease Progression & Virtual Populations

We utilize virtual population modeling to rigorously capture and simulate patient variability, clinical characteristics, and drug response profiles. Paired with disease progression modeling, this allows us to map the long-term dynamics of clinical endpoints and biomarkers, significantly de-risking your clinical phase transitions.